| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.90 | 0.00 (0.00%) | 2.25 - 14.08 | 120.1 thousand (Below Avg) |
Market data as of 10:05AM 05/22/13. Quotes are delayed by at least 15 min.
| Open | 2.95 |
|---|---|
| Previous Close | 2.90 |
| Day's Range | 2.85 - 2.96 |
| Market Cap | 150.5M |
| Avg Volume (10 Day) | 2.3M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -2.56 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures
PR Newswire - Wednesday 05/22/2013 8:38 AM ET
Law Offices of Todd M. Garber Announces Investigation of AVEO Pharmaceuticals, Inc.
Business Wire - Monday 05/20/2013 9:32 AM ET
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
PR Newswire - Saturday 05/18/2013 9:00 AM ET
Aveo Pharmaceuticals, Inc. Sued by Investor
PR Newswire - Friday 05/17/2013 1:15 PM ET
AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
Business Wire - Wednesday 05/15/2013 6:00 PM ET
Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.
Business Wire - Tuesday 05/14/2013 9:02 PM ET
Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against AVEO Pharmaceuticals, Inc.
Business Wire - Tuesday 05/14/2013 4:30 PM ET
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
PR Newswire - Friday 05/10/2013 3:36 PM ET
| AVEO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -41.58% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.18 | |
| LT Debt/Equity | 0.12 | |
| Earnings Yield | -- | |
| Price/Sales | 8.03 |
| Company | Last | Change |
|---|---|---|
| ZIOPHARM Oncology Inc | 1.84 | +2.51% |
| Cell Therapeutics Inc | 1.30 | -1.54% |
| OncoGenex Pharmaceuticals Inc | 10.51 | +0.53% |
| Pacific Biosciences of California Inc | 2.53 | -0.30% |
| Geron Corp | 1.14 | +1.79% |
Data is delayed by at least 15 min.